Kidney transplantation (KT) is the foremost kidney replacement therapy for patients with end-stage kidney disease (ESKD). 1 There is firm evidence that KT benefits the prognosis and quality of life of ESKD patients, and the prognosis of KT has improved over time. 2 However, unresolved posttransplant complications are still observed, including metabolic disorders, malignant diseases, infectious diseases, or rejection, which are threatening to the survival of the allografts and recipients.As KT requires long-term immunosuppression, an increase in the infectious risk or reactivation of Mycobacterium tuberculosis (TB), one of the Top 10 causes of global deaths, 3 is seen after KT. 4 TB after KT is associated with greater risks of allograft failure and posttransplant deaths, 5-8 which has been reported mainly in Western countries. Thus, active TB after KT is considered an important infectious complication in KT recipients. Current guidelines recommend routine screening for TB in potential recipients, and complete treatment or prophylactic measures are necessary according to the